The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Highlights in PTCL at ASH 2022
Neha Mehta-Shah, MD, Washington University in St Louis, St Louis, MO, comments on key peripheral T-cell lymphoma (PTCL) abstracts presented at ASH 2022, including the ORACLE trial (NCT03593018). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genetech/Roch: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Corvus Pharmaceuticals: Research Funding; Celgene: Research Funding; Bristol Myers-Squibb: Research Funding; AstraZeneca: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Karyopharm Therapeutics: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Kyowa Hakko Kirin Co., Ltd.: Membership on an entity’s Board of Directors or advisory committees; Secura Bio: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Verastem: Research Funding.
